KCR

#KCRScienceRead Drug for rare form of Alzheimer’s “scientifically promising,” the recent research shows. In today's #KCRScienceRead we would like to highlight recent findings (for the first time in a clinical trials) indicating "that early removal of amyloid plaques in the brain years before symptoms are observed, may delay onset of Alzheimer’s dementia."? "Researchers investigated the effects of the experimental anti-amyloid drug gantenerumab to determine whether it could prevent participants developing dementia. The data offers new evidence supporting the amyloid hypothesis of Alzheimer’s." Read more in the News from European Pharmaceutical Review: https://lnkd.in/dkc5bCnf #Alzhaimer, #clinicalresearch, #KCRCRO

What's going on in the world of #Biosimilars? KCR Principal Consultant, Dr. Dave Li, and KCR Chief Medical Officer, Dr. Anna Baran, published a #whitepaper to tell you! The article, "The Imperfect Art of Biosimilars” works to dissect interchangeability for biosimilars and offers operational perspectives for consideration in the design and execution of clinical studies on biosimilars. Check it out!

??#AreYourKidneysOK? On #WorldKidneyDay, we encourage you to learn more about your kidney health - because these vital organs work tirelessly to keep you healthy. But how well do you know their condition? Take our quick kidney health quiz and find out if your kidneys are in good shape! Simply follow the link below.?? https://lnkd.in/eF-sguYb

#PatientSafetyAwarenessWeek highlights the importance of healthcare safety and the collective efforts to enhance patient well-being. It encourages healthcare professionals, organizations, and patients to engage in discussions and initiatives that promote best practices, reduce errors, and improve communication. By fostering a culture of safety, we can ensure more effective and reliable care for all.

#KCRScienceRead The SECuRE trial has moved into Phase 2 (cohort expansion) after demonstrating remarkable PSA reductions in pre-chemo participants! The Safety Review Committee has approved increasing dose levels (up to 8 GBq) and treatment cycles (up to 6). ?? Key Findings: ? 68% of participants saw PSA drops, even after just one dose of 67Cu-SAR-bisPSMA. ? Pre-chemo participants responded exceptionally well – nearly half experienced PSA reductions of 80% or more. ? One participant achieved a complete response after just two doses (12 GBq). ? Disease control was achieved in 92% of pre-chemo participants. Dr. Alan Taylor, Clarity’s Executive Chairperson, shared: “The SECuRE trial continues to generate extraordinary results, and we are thrilled to progress to phase 2.” With expanded enrollment and a new combination therapy approach, this trial is shaping the future of prostate cancer treatment! ?? Read more here ?? https://lnkd.in/dF9NrTx8 #ProstateCancer #ClinicalTrials #Oncology #MedicalResearch

?? March 4 is #WorldObesityDay – a crucial moment to recognize obesity as a complex, chronic disease and a key driver of other serious health conditions. ?? Obesity is a global public health crisis, fueling the rise of diabetes, heart disease, and cancer. Addressing it isn't just about weight—it’s about reducing the burden of chronic diseases worldwide. ?? It's time for action. By raising awareness, advocating for better policies, and supporting those affected, we can make a real difference. ?? Learn more here: https://lnkd.in/eS38U52 #WorldObesityDay #PublicHealth #ChronicDisease

In today's #KCRScienceRead, we explore a groundbreaking experimental #cancer treatment developed by Professor Georgina Long AO, recently published in Nature Medicine, showing promising early results for glioblastoma, one of the deadliest brain cancers. ?? This marks the first-ever documented use of neoadjuvant triple immunotherapy for glioblastoma—leveraging melanoma research to boost the immune system before surgery. The results? When the tumor was removed, it showed increased diversity, abundance, and activation of immune cells—a potential sign of a strong immune response. ?? “My hypothesis was that we could administer combination immunotherapy as first-line treatment before surgery to boost the immune system and activate T-cells to target the brain tumour — an approach I had previously developed successfully in both stage 3 melanoma and melanoma that had spread to the brain,” said Professor Long. Now, an Australian-led international clinical trial is in the works, led by Dr. Jim Whittle, to determine if this approach could offer real hope to glioblastoma patients. ?? Click to read more! https://lnkd.in/ggz_WzYN #CancerResearch #Immunotherapy #Glioblastoma #MedicalBreakthrough #Oncology

“Overall, #GenAI would have significant impacts on drug discovery and downstream clinical developments, transforming future clinical development models following clinical data sharing initiatives with predictive analytics approaches augmented by multimodal reasoning anchoring on real-world data empowered by GenAI deep learning algorithms.” ??KCR Chief Medical Officer, Anna Baran, and Principal Consultant, Dave Li, MD, PhD, published an article in Applied Clinical Trials that details the transformative potential of generative artificial intelligence (#GenAI) in revolutionizing clinical trials and #drug #development. Check it out!???

?? A Paradigm Shift in Bladder Cancer Treatment? #KCRScienceRead Radiation + Immunotherapy Shows Promise for Bladder Preservation Radical cystectomy remains the standard of care for muscle-invasive bladder cancer (MIBC)—but it comes with profound quality-of-life challenges. Now, findings from the IMMUNOPRESERVE clinical trial, published in Clinical Cancer Research (AACR), suggest a promising bladder-preserving alternative: radiation combined with the immune checkpoint inhibitors durvalumab and tremelimumab. Led by Dr. Xavier Garcia-del-Muro (University of Barcelona), the phase II study reported remarkable outcomes: ? 93% complete response rate ? 84% two-year overall survival ? 83% metastasis-free survival ? 94% of patients preserved their bladders after 27 months According to Garcia-del-Muro, “this multimodal bladder-preserving approach is feasible, showing high efficacy in terms of response and long-term bladder preservation.” He emphasizes the need for larger trials to validate these findings but highlights the potential of immunotherapy plus radiation to improve quality of life without compromising survival. Click to read more?? https://lnkd.in/gbDNk5NM #BladderCancer #Oncology #Immunotherapy #RadiationTherapy #CancerResearch #MedicalInnovation

"Selecting appropriate sites is one of the most crucial factors for determining successful completion of a #clinicaltrial. It is important to ensure that potential sites have the capability to meet the #protocol requirements and the capacity to deliver the study objectives in a safe and efficient manner." Check out this #WhitePaper from KCR Consultant, ?aneta Szkar?at, where she shares some practical strategies toward optimizing the site feasibility assessment.?